13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q2 2024. See the latest, Q2 2026 →

Reported value

$1.97B

−21% on the quarter before

Positions

2 new · 3 sold out

Top 10

88.6%

of the value

Est. gain

−$327.0M

on stocks held all quarter

Est. return

−14.6%

on those stocks since Q1 2024

Filed

Aug 2, 2024

On SEC EDGAR ↗

Positions as of Jun 30, 2024, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q1 2024. Striped tiles are options.

Gitlab Inc25%

Arm Holdings Plc16%

Revolution Medicines Inc10%

CrowdStrike8.3%

Freshworks Inc7.9%

Dexcom Inc6.0%

UiPath4.5%

Prime Medicine Inc3.9%

Snowflake3.7%

Verve Therapeutics Inc3.1%

Planet Labs Pbc3.0%

Tempus AI2.7%

18 others1.2%

0.8%

0.5%

Gitlab Inc25%

Arm Holdings Plc16%

Revolution Medicines Inc10%

CrowdStrike8.3%

Freshworks Inc7.9%

Dexcom Inc6.0%

UiPath4.5%

Prime Medicine Inc3.9%

Snowflake3.7%

Verve Therapeutics Inc3.1%

Planet Labs Pbc3.0%

Tempus AI2.7%

18 others1.2%

0.8%

0.5%

Largest buys

Since Q1 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Tempus AI~$54.3MNew · 0.0% → 2.7%+1,551,102 shares
Desktop Metal Inc~$4.6MNew · 0.0% → 0.2%+1,104,871 shares
Revolution Medicines Inc~$215,900Added · 6.8% → 10.4%+5,563 shares

Largest sells

Since Q1 2024, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

CrowdStrike~$164.0MCut · 10.9% → 8.3%−427,894 shares
Dexcom Inc~$85.5MCut · 9.9% → 6.0%−753,836 shares
Invivyd Inc~$20.1MSold out · 0.8% → 0.0%−4,527,122 shares
Desktop Metal Inc~$9.7MSold out · 0.4% → 0.0%−11,048,730 shares
Mondee Holdings Inc~$42,550Sold out · 0.0% → 0.0%−18,420 shares

Holdings

As of Jun 30, 2024. Changes are in shares against Mar 31, 2024, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Gitlab IncCLASS A COM · shares 0% · price −14.7%	24.6%	22.6%	$485.2M	9.8M	0%	$49.72	$58.32	−14.7%	−$83.9M
2	Arm Holdings PlcSPONSORED ADS · shares 0% · price +30.9%	16.3%	9.7%	$320.8M	2.0M	0%	$163.62	$124.99	+30.9%	+$75.7M
3	Revolution Medicines IncCOM · shares +0.1% · price +20.4%	10.4%	6.8%	$206.0M	5.3M	+0.1%	$38.81	$32.23	+20.4%	+$34.9M
4	CrowdStrikeCL A · shares −50% · price +19.5%	8.3%	10.9%	$164.0M	427,895	−50%	$383.19	$320.59	+19.5%	+$26.8M
5	Freshworks IncCLASS A COM · shares 0% · price −30.3%	7.9%	8.9%	$156.6M	12.3M	0%	$12.69	$18.21	−30.3%	−$68.1M
6	Dexcom IncCOM · shares −42% · price −18.3%	6.0%	9.9%	$117.6M	1.0M	−42%	$113.38	$138.70	−18.3%	−$26.3M
7	UiPathCL A · shares 0% · price −44.1%	4.5%	6.3%	$89.2M	7.0M	0%	$12.68	$22.67	−44.1%	−$70.3M
8	Prime Medicine IncCOM · shares 0% · price −26.6%	3.9%	4.2%	$77.4M	15.1M	0%	$5.14	$7.00	−26.6%	−$28.0M
9	SnowflakeCL A · shares 0% · price −16.4%	3.7%	3.4%	$72.4M	535,604	0%	$135.09	$161.60	−16.4%	−$14.2M
10	Verve Therapeutics IncCOM · shares 0% · price −63.3%	3.1%	6.5%	$60.3M	12.3M	0%	$4.88	$13.28	−63.3%	−$103.7M
11	Planet Labs PbcCOM CL A · shares 0% · price −27.1%	3.0%	3.2%	$59.4M	31.9M	0%	$1.86	$2.55	−27.1%	−$22.0M
12	Tempus AICL A · shares New	2.7%	—	$54.3M	1.6M	New	$35.00	—	—	—
13	Sana Biotechnology IncCOM · shares 0% · price −45.4%	0.78%	1.1%	$15.4M	2.8M	0%	$5.46	$10.00	−45.4%	−$12.8M
14	Relay Therapeutics IncCOM · shares 0% · price −21.4%	0.52%	0.52%	$10.2M	1.6M	0%	$6.52	$8.30	−21.4%	−$2.8M
15	Vera Therapeutics IncCL A · shares 0% · price −16.1%	0.44%	0.41%	$8.7M	241,264	0%	$36.18	$43.12	−16.1%	−$1.7M
16	Lyell Immunopharma IncCOM · shares 0% · price −35.0%	0.43%	0.52%	$8.5M	5.9M	0%	$1.45	$2.23	−35.0%	−$4.6M
17	Oscar Health IncCL A · shares 0% · price +6.4%	0.39%	0.29%	$7.6M	481,988	0%	$15.82	$14.87	+6.4%	+$457,889
18	Beam Therapeutics IncCOM · shares 0% · price −29.1%	0.38%	0.42%	$7.5M	321,604	0%	$23.43	$33.04	−29.1%	−$3.1M
19	Tscan Therapeutics IncCOM · shares 0% · price −26.3%	0.32%	0.34%	$6.3M	1.1M	0%	$5.85	$7.94	−26.3%	−$2.3M
20	Illumina IncCOM · shares 0% · price −24.0%	0.28%	0.29%	$5.6M	53,470	0%	$104.38	$137.32	−24.0%	−$1.8M
21	Monte Rosa Therapeutics IncCOM · shares 0% · price −47.0%	0.28%	0.41%	$5.5M	1.5M	0%	$3.74	$7.05	−47.0%	−$4.8M
22	Dianthus Therapeutics IncCOM · shares 0% · price −13.7%	0.27%	0.25%	$5.4M	208,697	0%	$25.88	$30.00	−13.7%	−$859,832
23	Desktop Metal IncCOM CL A · shares New	0.23%	—	$4.6M	1.1M	New	$4.13	—	—	—
24	Foghorn Therapeutics IncCOM · shares 0% · price −14.3%	0.15%	0.13%	$2.9M	500,901	0%	$5.75	$6.71	−14.3%	−$480,864
25	Tenaya Therapeutics IncCOM · shares 0% · price −40.7%	0.14%	0.19%	$2.8M	915,705	0%	$3.10	$5.23	−40.7%	−$2.0M
	Total · 42 positions	100%		$1.97B						−$327.0M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q1 2024 to Q2 2024: 38 stocks held throughout, down $327.0M (−14.6%).

Arm Holdings Plc+$75.7M+31%
Revolution Medicines Inc+$34.9M+20%
CrowdStrike+$26.8M+20%
Oscar Health Inc+$457,889+6%
Rani Therapeutics Hldgs Inc+$309,460+22%
Prime Medicine Inc−$28.0M−27%
Freshworks Inc−$68.1M−30%
UiPath−$70.3M−44%
Gitlab Inc−$83.9M−15%
Verve Therapeutics Inc−$103.7M−63%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗